Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 4.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.15 | - |
NAV | ₹29.78 | - |
Fund Started | 04 Dec 2015 | - |
Fund Size | ₹1287.45 Cr | - |
Exit Load | Exit load of 0.25% if redeemed within 30 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 26.90% | - |
3 Year | 20.49% | - |
5 Year | 25.50% | - |
1 Year
3 Year
5 Year
Equity | 94.90% | - |
Cash | 5.10% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.78% |
Aurobindo Pharma Ltd. | 7.68% |
Lupin Ltd. | 7.51% |
Dr. Reddy's Laboratories Ltd. | 6.63% |
Cipla Ltd. | 5.82% |
Divi's Laboratories Ltd. | 4.97% |
Fortis Healthcare Ltd. | 4.78% |
Zydus Lifesciences Ltd. | 3.56% |
Apollo Hospitals Enterprise Ltd. | 3.34% |
Alkem Laboratories Ltd. | 3.29% |
Name | Meeta Shetty | - |
Start Date | 09 Nov 2018 | - |
Name
Start Date
Description | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. | - |
Launch Date | 04 Dec 2015 | - |
Description
Launch Date